Form 4 for NDRA ENDRA Life Sciences Inc.
Accepted 2022-12-13 00:00:00 ET · period of report 2022-12-09 · accession 0001209191-22-060895 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-13 | 2022-12-09 | NDRA | Thornton Michael Milos | CTO | P - Purchase | $3.40 | +1,500 | 19.1K | +9% | +$5,100 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-09 | P | A | 1,500 | $3.40 | 19,139 | D | — | — | (F1) On December 9, 2022, the Issuer effected a 1-for-20 reverse stock split (the "Reverse Stock Split") of its outstanding Common Stock. The number of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. |